0001104659-17-043883.txt : 20170706 0001104659-17-043883.hdr.sgml : 20170706 20170706171841 ACCESSION NUMBER: 0001104659-17-043883 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170703 FILED AS OF DATE: 20170706 DATE AS OF CHANGE: 20170706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mersana Therapeutics, Inc. CENTRAL INDEX KEY: 0001442836 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-498-0020 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: MERSANA THERAPEUTICS INC DATE OF NAME CHANGE: 20080813 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Protopapas Anna CENTRAL INDEX KEY: 0001347582 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38129 FILM NUMBER: 17953202 MAIL ADDRESS: STREET 1: MILLENNIUM PHARMACEUTICALS, INC. STREET 2: 40 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 a4.xml 4 X0306 4 2017-07-03 0 0001442836 Mersana Therapeutics, Inc. MRSN 0001347582 Protopapas Anna C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2017-07-03 4 C 0 72263 A 192565 I By Kinney/Protopapas Family Irrevocable Trust Series B-1 Convertible Preferred Stock 2017-07-03 4 C 0 325189 0 D Common Stock 72263 0 I By Kinney/Protopapas Family Irrevocable Trust Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into .22222 shares of Common Stock without payment of further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock. These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. /s/ Eva M. Jack, as Attorney-in-Fact 2017-07-06